---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-005013"
form_type: "8-K"
ticker: "LITS"
cik: "0001262104"
company_name: "Lite Strategy, Inc."
filed_at: "2024-01-17T23:59:59+00:00"
generated_at: "2026-06-06T22:27:52.540929+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# MEI Pharma enters new CMO employment agreement; $503K salary, 40% bonus

## Summary
- Dr. Richard Ghalie continues as CMO under new agreement effective Jan 16, 2024; base salary $503,165.28, target bonus 40% of base.
- Termination without cause or for good reason: lump sum 12 months base, COBRA for 12 months, pro-rata bonus, 12-month option vesting acceleration.
- Change in control: full vesting of options if terminated without cause in 3 months before or 2 years after CIC.
- Death or disability triggers additional 12-month option vesting acceleration.
- Agreement aligns terms with other senior executives; replaces prior 2016 employment letter.

## SEC filing metadata
- accession: 0000950170-24-005013
- form_type: 8-K
- ticker: LITS
- cik: 0001262104
- company_name: Lite Strategy, Inc.
- filed_at: 2024-01-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1262104/000095017024005013/0000950170-24-005013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1262104/000095017024005013/meip-20240116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-005013
- JSON: https://secwatch.observer/filing/0000950170-24-005013.json
- Plain text: https://secwatch.observer/filing/0000950170-24-005013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.